



1057

Survival Study(4S),²⁾ Cholesterol and Recurrent Events Trial(CARE),³⁾⁴⁾ Long - Term Intervention with Pravastatin in Ischaemic Disease Study(LI - PID)가⁵⁾

Scandinavian simvastatin survival Study(4S)

가 210 mg/dL 4444 Scandinavian simvastatin 5.4 25%, 35%, 8% 가 30%, 42% (major coronary events) 34% Table 1 가

Cholesterol and recurrent events trial(CARE) 가 240 mg/dL 4159 pravastatin 5 20%, 28%(32%) 5% 가

Table 1. Scandinavian simvastatin survival study에서 남성과 여성사이에 예방효과의 비교

	Placebo	Drug	RR(95% CI)
Total Death			
Women	25/420 (6.0%)	27/407 (6.6%)	1.12 (0.65 - 1.93)
Men	231/1803 (12.8%)	155/1814 (8.5%)	0.66 (0.53 - 0.80)
Major coronary event			
Women	91/420 (21.7%)	59/407 (14.5%)	0.65 (0.47 - 0.91)
Men	531/1803 (29.4%)	372/1814 (20.5%)	0.66 (0.58 - 0.76)

24% 125 mg/dL, 125 150 mg/dL, >150 mg/dL 3 125 mg/dL

가 가 20%

46% Long - term intervention with pravastatin in ischaemic disease study(LIPID)

가 155 271 mg/dL 9014 pravastatin 6.1 18%, 25%, 5%, 22%, 24%

가 일차예방연구

, HMG CoA reductase West of Scotland Coronary Prevention Study(WOSCOPS),⁶⁾ Air Force /Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)가⁷⁾ West of scotland coronary prevention study(WO - SCOPS)

Table 2. HMG CoA reductase 억제제를 사용한 관동맥 예방 연구에서 남녀간에 효과의 비교

WOSCOPS	6595/0	± / *	+ / *	+ / *	+ / *
AFCAPS/TexCAPS	5608/997	- / -	- / -	- / -	+ / -
4S	3617/827	+ / -	+ / ?	+ / ?	+ / +
CARE	3583/576	- / -	- / -	- / -	+ / +
LIPID	7498/1516	+ / -	+ / -	+ / -	+ / -
/ . + : , ± : , - : , * : , ? :					

가 155 232 mg/dL
6595
vastatin 4.9
20%,
26% , 5% 가
22%
가 (p=0.051), reductase
28%(p
=0.13),
33%(p=0.042) 가
(Table 2).
AFCAPS/TexCAPS
가 1/4
180 264 mg/dL,
가 130 190 mg/dL,
47 mg/dL , 45
mg/dL 가 가
6605 가
lovastatin 5.2
18%, 가
25% ,
6% 가
가 가 ,
(>265 mg/dL, ?)
37% 가
36% 46%
가 가 /

가

, 가

가

가

REFERENCES

- 1) American Heart Association. 2000 Heart and Stroke, Statistical Update. Dallas, Texas. American Heart Association, 1999.
- 2) Scandinavian Simvastatin Survival Study Group. *Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)*. *Lancet* 1994;344:1383-9.
- 3) Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. *The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators*. *N Engl J Med* 1996;335:1001-9.
- 4) Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, et al. *Braunwald E. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial*. *J Am Coll Cardiol* 1998;32:140-6.
- 5) The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels*. *N Engl J Med* 1998;339:1349-57.
- 6) Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. *Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group*. *N Engl J Med* 1995;333:1301-7.
- 7) Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. *Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study*. *JAMA* 1998;279:1615-22.
- 8) Genazzani AR, Gambacciani M. *Hormone replacement therapy: the perspectives for the 21st century*. *Maturitas* 1999;32:11-7.
- 9) Kim CH, Jang HC, Cho DH, Min YK. *Effects of Hormone Replacement Therapy on Lipoprotein (a) and Lipid in Postmenopausal Women*. *Atheroscler Thromb* 1994;14:275-81.
- 10) Kim CJ, Ryu WS, Kwak JW, Park CT, Ryoo UH. *Changes in Lp (a) Lipoprotein and Lipid Levels after Cessation of Female Sex Hormone Production and Estrogen Replacement*. *Arch Intern Med* 1996;156:500-4.
- 11) Farmer JA, Gotto AM Jr. *Dyslipidemia and other risk factors for coronary artery disease*. In: Braunwald, *Heart Disease. A Textbook of Cardiovascular Medicine*. 5th ed. Saunders;1997. p.1126-60.
- 12) Kannel WB. *Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study*. *Am Heart J* 1987;114:413-9.
- 13) Lerner DJ, Kannel WB. *Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population*. *Am Heart J* 1986;111:383-90.
- 14) Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. *High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study*. *Am J Med* 1977;62:707-14.
- 15) Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. *Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study*. *Circulation* 1987;75:1102-9.
- 16) Bush TL, Fried LP, Barrett-Connor E. *Cholesterol, lipoproteins, and coronary heart disease in women*. *Clin Chem* 1988;34:B60-70.
- 17) . 1998
- 18) Douglas PS. *Coronary Artery Disease in Women*. In: Braunwald, *Heart Disease. A Textbook of Cardiovascular Medicine*. 5th ed. Saunders; 1997. p.1704-14.
- 19) Mautner SL, Lin F, Mautner GC, Roberts WC. *Comparison in women versus men of composition of atherosclerotic plaques in native coronary arteries and in saphenous veins used as aortocoronary conduits*. *J Am Coll Cardiol* 1993;21:1312-8.
- 20) Ernst N, Fisher M, Bowen P, Schaefer EJ, Levy RI. *Changes in plasma lipids and lipoproteins after a modified fat diet*. *Lancet* 1980;2:111-3.
- 21) Brownell KD, Bachorik PS, Ayerle RS. *Changes in plasma lipid and lipoprotein levels in men and women after a program of moderate exercise*. *Circulation* 1982;65:477-84.
- 22) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. *The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial*. The Writing Group for the PEPI Trial. *JAMA* 1995; 273:199-208.
- 23) Knopp RH. *The effect of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease*. *Obstet Gynecol* 1988;72:23S-30S.
- 24) Wenger NK. *Postmenopausal hormone use for cardioprotection: what we know and what we must learn*. *Curr Opin Cardiol* 1999;14:292-7.
- 25) Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. *Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women*. *Heart and Estrogen/progestin Replacement Study (HE-RS) Research Group*. *JAMA* 1998; 280:605-13.
- 26) Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. *Menopausal estrogen and estrogen/progestin replacement therapy and breast cancer risk*. *JAMA* 2000; 283:485-91.